Although the use of vitamin D or synthetic VDR agonist as disease-modifying agents represents an attractive therapeutic concept for cholestatic liver diseases, especially when vitamin D levels are already low because of cholestasis, data from controlled studies are lacking. The gene discussed is VDR; the disease is Cholestatic liver disease.